Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients
Launched by AKDENIZ UNIVERSITY · Dec 14, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Coming to Antalya Training and Research Hospital Medical Oncology unit for treatment,
- • First time taking one of the immune checkpoint inhibitors (Ipilimumab CTLA-4, Pembrolizumab PD-1, Nivolumab PD-1, Atezolizumab PDL-1),
- • Speaking and understanding Turkish,
- • Being literate,
- • 18 Years and older
- • With solid tumor,
- • No communication barrier
- • Being able to communicate by phone
- • Individuals who agree to participate in the research.
- Exclusion Criteria:
- • Patients receiving other cancer treatments in combination with immunotherapy,
- • Patients with Eastern Cooperative Oncology Group Performance Scale 4.
Trial Officials
Fatma Arikan
Study Director
Akdeniz University
About Akdeniz University
Akdeniz University is a leading academic institution located in Antalya, Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Akdeniz University leverages its extensive expertise and state-of-the-art facilities to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a diverse range of stakeholders, including healthcare professionals, researchers, and industry partners, to conduct rigorous clinical trials that adhere to the highest ethical and scientific standards. Through its dedication to excellence in research, Akdeniz University plays a pivotal role in contributing to the development of new therapies and enhancing the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antalya, , Turkey
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials